AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate UpdateLandmark exclusive option and license deal with Takeda for ...
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potent ...
These shares are ending the week in the red. But why? For over a decade now, we've been helping Australian investors – just like you! – become more confident investors. And to help new investors get ...
Morning, y’all! Full moon tonight. Not just any full moon, but a full blood worm moon total lunar eclipse! Say that five times fast. Let’s get to it.